New predictive models are key to building the bridge between clinical trials and precision medicine.
The applications surrounding more personalized approaches to prevention and treatment are endless, but collecting the necessary clinical data can present conceptual and practical challenges. At the DCRI, researchers are collaboratively developing registries, research programs, and partnerships in service of personalized medicine. Working together, we can transform the way conditions such as cancer and heart disease are treated.
Kristin Newby, MD, MHSProfessor of Medicine, Cardiology
"What if we tailored disease therapies and prevention to each individual’s unique environmental, sociocultural and biological profile?"
Kristin Newby on the MURDOCK Study
Kristin Newby, MD, MHS, principal investigator for the MURDOCK Study, discusses how the study is the next step in understanding diseases at a genetic level.
Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
Comment on Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Collaboration: The MURDOCK Study
The MURDOCK Study, or the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis, is Duke University’s longitudinal health study working to reclassify health and disease through advanced scientific technologies, expertise from Duke researchers, and close collaboration with our strong network of local and regional community partners.